- Home
- GSBC vs IOVA Comparison
GSBC vs IOVA Comparison
Compare GSBC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSBC
- IOVA
- Stock Information
- Founded
- GSBC 1923
- IOVA 2007
- Country
- GSBC United States
- IOVA United States
- Employees
- GSBC N/A
- IOVA N/A
- Industry
- GSBC Major Banks
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GSBC Finance
- IOVA Health Care
- Exchange
- GSBC Nasdaq
- IOVA Nasdaq
- Market Cap
- GSBC N/A
- IOVA 1.0B
- IPO Year
- GSBC N/A
- IOVA N/A
- Fundamental
- Price
- GSBC $56.67
- IOVA $1.72
- Analyst Decision
- GSBC Hold
- IOVA Strong Buy
- Analyst Count
- GSBC 2
- IOVA 9
- Target Price
- GSBC $59.50
- IOVA $18.22
- AVG Volume (30 Days)
- GSBC 32.0K
- IOVA 9.3M
- Earning Date
- GSBC 04-16-2025
- IOVA 05-08-2025
- Dividend Yield
- GSBC 2.85%
- IOVA N/A
- EPS Growth
- GSBC 10.51
- IOVA N/A
- EPS
- GSBC 5.60
- IOVA N/A
- Revenue
- GSBC $219,572,000.00
- IOVA $164,070,000.00
- Revenue This Year
- GSBC N/A
- IOVA $182.20
- Revenue Next Year
- GSBC $0.33
- IOVA $62.10
- P/E Ratio
- GSBC $10.02
- IOVA N/A
- Revenue Growth
- GSBC N/A
- IOVA 13698.99
- 52 Week Low
- GSBC $47.57
- IOVA $2.70
- 52 Week High
- GSBC $68.02
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- GSBC 60.00
- IOVA 24.56
- Support Level
- GSBC $53.60
- IOVA $3.02
- Resistance Level
- GSBC $57.70
- IOVA $3.31
- Average True Range (ATR)
- GSBC 1.60
- IOVA 0.24
- MACD
- GSBC 0.37
- IOVA -0.08
- Stochastic Oscillator
- GSBC 89.78
- IOVA 6.00
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.